Press releases
- Innovent Dosed First Participant in Phase 3 Clinical Study (Neoshot) of IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab for MSI-H/dMMR Colon Cancer Neoadjuvant Therapy
- Innovent Announces 2023 Annual Results and Business Updates
- Innovent Announces Primary Endpoint Met in the Second Phase 2 Clinical Trial of IBI302 (anti-VEGF/complement) in Treating Neovascular Age-related Macular Degeneration (nAMD)
- Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2024 AACR Annual Meeting
- Innovent released the results of two clinical studies of IBI311 (an anti-IGF-1R monoclonal antibody) in oral presentations at the Asia-Pacific Academy of Ophthalmology Congress and International Congress of Endocrinology 2024
- Innovent Announces First Participant Dosed in a Phase I Study of IBI3002 (an anti-IL-4Rα/TSLP bispecific antibody) in Australia
- Innovent Announces Primary Endpoint Met in the Phase 3 Clinical Trial (RESTORE-1) of IBI311 (Anti-IGF-1R Antibody) in Treating Thyroid Eye Disease and Plans to Submit NDA to the NMPA
- Innovent's First New Drug Application of Mazdutide for Chronic Weight Management has been Accepted by the NMPA of China
- Innovent Announces Retirement of CFO and Appointment of New CFO
- Innovent Announces the First Phase 3 Clinical Trial of Mazdutide in Chinese Adults with Overweight or Obesity Met the Primary and All Key Secondary Endpoints, and Plans to Submit NDA of Mazdutide to the NMPA
More ▼
Key statistics
On Wednesday, Innovent Biologics Inc (1801:HKG.HZ) closed at 38.45, 40.84% above the 52 week low of 27.30 set on Aug 08, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 38.40 |
---|---|
High | 39.10 |
Low | 38.00 |
Bid | 38.40 |
Offer | 38.45 |
Previous close | 38.55 |
Average volume | 12.14m |
---|---|
Shares outstanding | 1.62bn |
Free float | 1.51bn |
P/E (TTM) | -- |
Market cap | 61.17bn HKD |
EPS (TTM) | -0.7056 HKD |
Data delayed at least 15 minutes, as of Mar 27 2024.
More ▼